Palatin Technologies is a cutting-edge brand that focuses on developing therapeutics to combat harmful inflammation. With their unique approach, they directly engage the body's natural pathways to resolve inflammation, resulting in groundbreaking treatments. Their flagship product, Vyleesi®, has shown impressive growth with a 14% increase in prescriptions dispensed over the previous quarter.

This growth has continued for six consecutive quarters, highlighting the effectiveness of their innovative solutions. Palatin Technologies is dedicated to leveraging their expertise in the melanocortin system to address a range of inflammatory and autoimmune diseases, particularly with a focus on ocular conditions. Their vision is driven by a future-focused intention and data-driven innovation.

As a brand, they prioritize a fast-paced, collaborative working environment where science and business seamlessly merge. Under the leadership of Chief Executive Officer Dr. Carl Spana and Chief Financial Officer Stephen T.

Wills, Palatin Technologies combines scientific expertise with strategic business acumen. They lead a team that is committed to developing innovative treatments that harness the power of the melanocortin system. Additional support from Chief Legal Officer Stephen A.

Slusher and Chief Medical Officer Dr. Michael B. Raizman further strengthens the brand's commitment to scientific excellence.

Download their corporate presentation to learn more about Palatin Technologies' pioneering work and their unwavering dedication to resolving inflammation and improving patient outcomes